Evidence map›Paper›PMID 40999983›Full record

ArticleMolecular medicine reports2025

Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell‑based therapeutic interventions.

Qihang Yan, Wuguang Chang, Wingshing Wong, Li Gong, Dachuan Liang, Jie Yang, Junye Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qihang Yan *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Wuguang Chang *Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China.
Wingshing Wong *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Li GongState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Dachuan LiangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Jie YangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Junye WangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol metabolism reprogramming serves a pivotal role in tumor onset and progression. The present study investigated lung adenocarcinoma (LUAD), focusing on the regulatory impact of cholesterol metabolism‑related genes (CMRGs). Consensus clustering identified distinct cholesterol metabolism‑related clusters in LUAD, followed by survival analysis and immune infiltration profiling for each cluster. A predictive model, constructed using cluster‑specific differentially expressed genes and the LASSO algorithm, was validated with an independent dataset. Furthermore, the model was utilized to predict potential responses to immunotherapy and chemotherapy for patients with LUAD. The functional role of the key gene GJB3 in LUAD progression was confirmed through

Indexed as

Adenocarcinoma of LungCholesterolConnexinsLung NeoplasmsBiomarkers, TumorCell Line, TumorCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorCholesterolConnexinsGJB3 protein, humancholesterol metabolismGJB3immunotherapylung adenocarcinomaprognosis

Identifiers

PMID40999983
PMCPMC12512528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.